Illumina Fined a Record $476 Million by the EU for Closing Grail Deal Before Approval

U.S. genetic testing company Illumina was fined a record 432-million-euro ($476 million) by the EU on Wednesday for closing its takeover of cancer test maker Grail before securing EU antitrust approval.

Illumina has been fighting the EU competition watchdog on several fronts since it was forced to seek its approval in 2021 despite the deal falling short of the EU turnover threshold for scrutiny.

The deal was eventually blocked last September, with regulators concerned that Illumina, once it had acquired Grail, would have an incentive to cut off Grail’s rivals from accessing its technology to develop blood-based early cancer detection tests to compete with Grail.

Read the source article at Yahoo Finance